However, few patients can benefit from these drugs because RET rearrangements have been described in approximately 10% to 20% of patients with papillary thyroid carcinoma and NTRK fusions in 5% to 25% of patients with DTC.7 This evidence concerns the gene RET and differentiated thyroid carcinoma.